# Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

Clinical trial · Novartis Pharmaceuticals

- Archive id: nct:NCT04023552
- Published: 2019-07-17
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT04023552
- Source URL: https://clinicaltrials.gov/study/NCT04023552
- Provenance: clinicaltrials

## Abstract

This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: Lp(a)HORIZON
- status: COMPLETED
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 8323
- sponsor: Novartis Pharmaceuticals
- conditions: Cardiovascular Disease and Lipoprotein(a)
- interventions: DRUG: TQJ230; DRUG: Placebo
- start date: 2019-12-12
- start date type: ACTUAL
- primary completion date: 2026-07-16
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [Cardiovascular Therapeutics](https://space-kitty.com/topics/cardiovascular-innovation)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.